We uncover the phenotypic and functional hematopoietic hierarchy operating in the early human embryo. It will bring insights into the mechanisms driving hematopoietic stem cell self-renewal for future cell therapies.
INTRODUCTION
Hematopoietic stem and progenitor cell (HSPC) transplantation is an important therapy used for over 40 years for patients suffering hematological malignancies. However the demand for clinical grade allogeneic HSPCs has significantly increased over the past decades with no parallel increase of the HSPC offer. A major goal in regenerative medicine is to derive HSPCs from several nonhematopoietic sources and manipulate them to treat patients. Despite many efforts, the generation of transplantable HSPCs from pluripotent stem cells or from directly reprogrammed cells is not yet possible. A similar remark applies for the conditions of HSPC amplification ex vivo.
These questions are calling for additional studies to identify the founders of the human hematopoietic system and the mechanism underlying HSPC emergence and amplification.
During embryonic development, the first hematopoietic cells (HCs) emerge in the yolk sac (YS) and generate primitive erythroblasts, macrophages and megakaryocytes (Tober et al., 2007; Palis et al., 1999; Silver and Palis, 1997; Luckett et al., 1978) . This first wave is followed by a second wave of erythro-myeloid progenitors also derived from the YS that gives rise to definitive erythroid, megakaryocyte, myeloid, and multipotent progenitors (Palis and Yoder, 2001; Palis et al., 1999 , Migliaccio et al., 1986 ) that seed the fetal liver and contribute to the generation of erythropoietic progenitors prior to HSPC colonization.
The first HSPCs emerge from specialized endothelial cells (EC), known as hemogenic endothelium (HE), in the aorta-gonad-mesonephros (AGM) region, migrate to the fetal liver to be massively amplified and finally reach the bone marrow (BM) their life-long residence (Ivanovs et al., 2017; Klaus and Robin, 2017; Crisan and Dzierzak, 2016; Ciau-Uitz and Patient, 2016; Julien et al., 2016; Medvinsky et al., 2011) . This conversion of endothelium into HCs termed endothelial-tohematopoietic transition (EHT) has been extensively verified in various animal model (Boisset et al., 2015 and Chen et al., 2011 and Bertrand et al., 2010; Kissa and Herbomel, 2010; Eilken et al., 2009; Zovein et al., 2008; Fraser et al., 2002; Jaffredo et al., 1998; Nishikawa et al., 1998a ) and we were among the first to probe this blood-forming potential in the human YS, AGM and Embryonic Liver (EL) (Oberlin et al., 2002) . These AGM-derived HSPCs are the founders of the definitive hematopoietic system. They display a dual endo-hematopoietic phenotype characterized by the expression of the endothelial-specific junctional vascular endothelial cadherin (Cdh5, CD144, hereafter designated as VEC) and the presence of the pan-leukocyte antigen CD45 (Ivanovs et al., 2014 ; Rybtsov et al., 2014 and Taoudi et al., 2008; Fraser et al., 2003; North et al., 2002; Nishikawa et al., 1998b) .
Since HSPCs produced in the AGM are likely to seed the EL, we hypothesized several years ago that cells expressing both endothelial and hematopoietic traits could also be detected in the human EL, in keeping with the situation described in the mouse fetal liver (Kim et al., 2005 , Taoudi et al., 2005 .
We indeed identified a sub-population of HSPCs in the human EL that co-expressed the endothelialspecific marker VEC, the pan-leukocyte antigen CD45 and the hemato-endothelial marker CD34 and we named this population 34DP since it expressed the CD34 antigen and was double positive (DP) for VEC and CD45. We showed that the 34DP cell fraction represented an intermediate between the hemogenic ECs that we previously identified in the human embryo (Oberlin et al., 2002) and the more advanced HC population that lacked VEC expression present in the late embryonic and fetal liver hematopoietic stages (Oberlin et al., 2010a and 2010b) . This 34DP subset displayed important selfrenewal and differentiation capacities, as detected by ex vivo and in vivo hematopoietic assays compared to its VEC negative counterpart. The 34DP population thus represents a potential model to study the earliest HSPCs in the human embryo and the mechanisms operating during their amplification and maturation. However the precise hematopoietic hierarchy operating at these stages was not known.
We report here an ensemble of phenotypic and functional characterizations (Figure 1 ) that allows hierarchically define the subpopulations present in the human EL hematopoietic HSPC compartment.
We used markers that typifies the most primitive HSPCs during adult (Majeti et al., 2007) and embryonic stages (Sinka et al., 2012; Ivanovs et al., 2017) , and in particular, the CD143 transmembrane molecule, also designated as Angiotensin-Converting Enzyme (ACE), identified as a cell surface marker of adult HSPCs (Jokubaitis et al., 2008) and known to be expressed on the earliest HSPCs in developing blood-forming tissues of the human embryo and fetus (Sinka et al., 2012) . We demonstrated that VEC, CD45 and CD34 in conjunction with ACE allows to separate several subpopulations endowed with contrasted hematopoietic potential and to identify a subpopulation uniquely able to maintain a proliferative potential and an undifferentiated state ex vivo and in vivo.
Moreover, we also tested whether other hematopoietic territories earlier in the developing human conceptus harbored cells with the 34DP signature and confirm that these cells can be identified in sites of HSPC emergence, including the YS, the AGM region and to a much lesser extend the placenta. In contrast, neither the cord blood nor the adult bone marrow carried cells with the 34DP signature. This work will help to identify the molecular mechanisms involved in the first human HSPC self-renewal and amplification to improve future therapies.
MATERIALS AND METHODS

Human tissues
Human embryos and fetuses from 5 to 9.6 weeks of gestation were obtained following voluntary abortions. Tissue collection and use were performed according to the guidelines and with the approval of the French National Ethic Committee (authorization N° PFS10_011). Developmental age was estimated based on several anatomic criteria according to the Carnegie classification for embryonic stages (O'Rahilly et al., 1987) and by ultrasonic measurements for fetal stages. Supplemental Table S1 recapitulates the stages of the embryonic and fetal tissues used in this study, as well as the type of experiments performed for each type of tissue.
Human umbilical cord blood (CB) samples were collected in citrate phosphate dextrose solution from healthy full-term newborns. CB samples were obtained through a partnership with the Cord Blood Bank of St Louis Hospital (Paris, France) which is authorized by the French Regulatory Authority (authorization N° PPC51).
Human bone marrow (BM) samples were collected from healthy individuals undergoing hip surgery (CHR Robert Ballanger hospitals, France).
All human samples were obtained with the written informed consents of subjects according to Helsinki declaration.
Cell preparation
Embryonic and fetal organs were excised sterilely using microsurgery instruments and a dissecting microscope, in phosphate-buffered saline (PBS) containing 100 U/ml penicillin and 100 mg/ml streptomycin (Invitrogen, Cergy-Pontoise, France). Tissues were dissociated for 1 hour at 37°C in Iscove's modified Dulbecco medium (IMDM; Invitrogen) containing 10% fetal calf serum (FCS; Hyclone Laboratories, Logan, UT), 0.1% type I/II/IV collagenase and type VIII hyaluronidase (Sigma-Aldrich, St Quentin Fallavier, France). Tissues were then disrupted mechanically through 18-, 23-and 26-gauge needles successively. Cell clumps were removed on a 50-μm nylon mesh (BD Biosciences, Le Pont de Claix, France).
CB and BM mononuclear cells (MNCs) were isolated by a Pancoll (Dutscher, Brumath, France) density gradient centrifugation.
All recovered cells were counted, after red blood cell lysis in 0.1% acetic acid. Cell viability was determined by 0.2% trypan blue exclusion (Invitrogen).
Sorting and cell analysis by flow cytometry
Monoclonal antibodies (Mabs) used for cell sorting or FACS analysis are listed in Supplemental   Table S2 . For cell sorting, cells were incubated for 30 min on ice with FITC-anti-CD45, PE-anti-VEcadherin, APC-anti-CD143 and APC-Alexa Fluor 750-anti-CD34 antibodies. Labeled cells were washed in PBS (Invitrogen) 0.2% bovine serum albumin (BSA) (Sigma-Aldrich), re-suspended in complete IMDM medium (Invitrogen), 10% fetal calf serum (FCS; Hyclone Laboratories), 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine (Invitrogen). Selected populations were sorted on a FacsDiva cell sorter (BD Biosciences). Sorted cells were systematically reanalyzed to establish purity.
Cells developed in culture were harvested by non-enzymatic treatment (Cell dissociation solution;
Sigma-Aldrich), washed in complete medium, labeled with fluorochrome-conjugated antibodies to hematopoietic and endothelial markers and analyzed on a FACSCalibur flow cytometer (BD Biosciences) using the CellQuest TM software (BD Biosciences).
BM cells collected from primary and secondary transplanted NSG mice were washed, labeled with fluorochrome-conjugated antibodies specific to human hematopoietic differentiation. Staining with lineage specific antibodies was performed concurrently with anti-human CD45 and anti-murine CD45
Mabs. Specificity of human Mabs was checked on BM cells from non-transplanted mice. Stained cells were analyzed on a FACScanto II cell analyser (BD Biosciences) using the FACSDiva TM software (BD Biosciences).
In all cases, background staining was evaluated using isotype-matched control antibodies and 7-Amino-Actinomycine D (7AAD) (Sigma-Aldrich) was used to gate dead cells out. increase between day 0 and day 12 of culture was obtained by calculating the ratio between the quantity of cells obtained at day 12 and the quantity of cells seeded at day 0.
-Long-term culture-initiating cell assay on MS-5 stromal cells
Sorted cells were cultivated in bulk on MS-5 mouse bone marrow stromal cells (Itoh et al., 1989) as previously described (Tavian et al., 2001) , except that only 3 human recombinant cytokines were added: 50 ng/ml stem cell factor, 1 ng/ml interleukin-15 and 5 ng/ml interleukin-2 (AbCys, Paris, HCs labeling by CFSE was carried out as described previously (Glimm and Eaves, 1999 
Cell cycle analysis
Quiescent (G 0 ) and cycling (G 1 and S+G 2 /M) cells were separated based on Hoechst/Pyronin-Y fluorescence as described (Shapiro, 1981 
Statistical Analysis
Data are representative of at least three independent experiments performed on different embryos and are expressed as mean ± standard deviation (SD). Statistical significance was determined using the non-parametric Mann-Whitney U test. P<0.001 *** was considered highly significant.
RESULTS
Phenotypic characterization of VE-cadherin + CD45 + double positive (DP) population in the human EL.
To document the hematopoietic hierarchies operating in the early human embryo, we searched for markers that would accurately identify recently emerged HSPCs in the EL. We first addressed the value of several markers used to identify human HSPC (Majeti et al., 2007) such as CD90 and CD117
(also known as c-KIT), CD38 and CD45RA. We also tested CD105 (also known as Endoglin), a wellknown endothelial marker (Cheifetz et al., 1992 populations. ELs were microdissected from embryos ranging from 5 to 9.6 weeks and dissociated by collagenase digestion and mechanical disruption and further processed for flow cytometry analysis and cell sorting ( Figure 1 and Supplemental Table S1 ). Figure 2A ). These populations were found along the different EL developmental stages examined albeit at different frequencies i.e., DP cells decreased with time ranging from 3.92% to 0.18% between 5 and 9.6-weeks of gestation (Supplemental Figure   S1 ). VEC expression was also found in more differentiated CD45 high cells (VEC + CD45 high ) ( Figure   2A ), likely monocytes, that expressed a low level of CD34 and myeloid lineage markers (data not shown). A large number of DP cells were positive for the HSPC markers CD34, CD90 and CD117
and were negative for CD38 and CD45RA, a phenotype likely associated with primitive progenitors, including stem cells. Conversely, most of the cells in the HC fractions were negative for the HSPC markers and positive for CD38 and CD45RA. CD105, a typical endothelial marker at that stage, was also found in DP but not in HCs hence confirming the endothelial signature of the DP population (Supplemental Table S3 ).
We also addressed the value of the angiotensin-converting enzyme (ACE, CD143) in combination with VEC, CD45 and CD34 antigens in the ECs, HCs and DP cells. Whole liver cell analysis demonstrated that ACE was expressed in both CD45 + and CD45 -cell population whereas it was mostly expressed in CD34 + cells ( Figure 2B ). A large number of VEC + CD45 -ECs (66.7±11%; Figure   2Ca ) and VEC low CD45 low DP cells (70.2±9%; Figure 2Cb ) expressed ACE while the HC fraction also contained ACE-expressing cells, but with a lower frequency (6.1±4% and 2±0.78% in VECAD Figure S2 .
CFC-assays
The presence of hematopoietic progenitors in each sorted cell population was first estimated by CFC assay. All cell populations contained hematopoietic progenitors, except 34LDPACE -cells.
34LHCACE
-produced very few, small, colonies and we did not further consider it. The greatest number of colonies was found in the 34HCACE + and 34HCACE -cell populations compared to the 34DPACE + cell population (233±10, 176.5±21 and 130±14 CFCs respectively) ( Figure 3A ).
However, the 34DPACE + cell population contained exclusively CFCs with high proliferative potential, whereas the 34HCACE -population only contained CFCs with low proliferative potential.
34HCACE
+ cells stood between the 34DPACE + and 34HCACE -cell populations and contained more CFC with low proliferative potential than high proliferative potential (131.5±26 and 45±6 respectively) ( Figure 3A ).
The proliferative capacity of CFCs cells was evaluated in each cell population by measuring the cell number fold-increase between day 0 and 12 of culture. The amplification of 34DPACE + cells was 4 fold higher than that of 34HCACE + and 20 fold higher than that of 34HCACE -cells ( Figure 3B ) hence revealing a strong proliferative capacity. Figure 3C shows typical CFU-GM and CFU-GEMM colonies obtained from each sorted cell populations and confirmed that colonies produce from 34DPACE + cells were always larger and more densely populated than colonies obtained from 34HCACE + or 34HCACE -cell populations.
Hematopoietic lineage distribution within colonies showed that 34DPACE + cell produced more CFU-G/M/GM colonies than BFU-E colonies (94±3 vs 20±6 respectively) whereas 34HCACE + and 34HCACE -cells produce more BFU-E colonies (128±15 and 185±12 respectively) than CFU-G/M/GM colonies (54±3 and 48±3 respectively). The number of multilineage CFU-GEMM colonies was the highest within 34DPACE + cells (16±5) and decreased two-folds in 34HCACE + cells (9±2) ( Figure 3D ). 34HCACE -cell population did not produce CFU-GEMM ( Figure 3D Figure 4B ).
In conclusion, our long-term culture assay, demonstrated that 34DPACE + cells showed a delayed but prolonged hematopoietic production when cultured on MS-5 cells, with a sustained maintenance of undifferentiated CD34 + CD45 low cells compared to 34HCACE + and 34HCACE -EL cells.
CSFE analysis
The proliferative capacity of the different EL cell subsets was probed at day 21 and 35 of MS-5 cocultures using CFSE staining. At 21 days of culture, 34DPACE + -derived CD45 + cells displayed more divisions than 34HCACE + -and 34HCACE --derived CD45 + counterparts. Of note, as early as day 3 after CSFE labeling, 34DPACE + cells already produced at least one or two more progenies than 34HCACE + and 34HCACE -cells ( Figure 5A ). Moreover, the first peak of division for 34DPACE + contained only 25.58 % of cells whereas it still contained 47.2% and 52.67 % of cells for 34HCACE + and 34HCACE -cultures respectively ( Figure 5A ). At day 6 after CSFE labeling, most 34DPACE + cells had performed up to 6 divisions and the first peak of proliferation was only containing 4.71 % of cells while 34HCACE + and 34HCACE -cells only produced 5 successive generations of HCs and the first peak of proliferation was still containing 15.32% and 26.85 % of cells respectively ( Figure 5A ).
At 35 day of culture, 34DPACE + cells generated the same number of progeny than the 34HCACE + and 34HCACE -cultures ( Figure 5B ) but produced more HCs with high proliferative potential than for 34HCACE + and 34HCACE -cells. Indeed, after 3 and 6 days of CSFE labeling the first peak of proliferation only contain 39.66% and 9.95% of cells for 34DPACE + co-culture whereas it still contain 56.98% and 43% and 70.85% and 53.28% of cells for 34HCACE + and 34HCACE -cultures respectively ( Figure 5B ) hence highlighting the superior proliferative response of 34DPACE + cells when co-cultured on MS-5.
Cell cycle analysis
We also performed cell cycle experiments using either Hoechst alone or both Hoechst and Pyronin Y. 
In Vivo Long term reconstituting ability is restricted to the 34DPACE + EL subset
To determine which cell population present in the human EL possessed the highest ability to engraft into immunocompromised mice, EL cell subsets were transplanted into sub-lethally irradiated NSG when 20,000 cells were injected (Supplemental Table S4 ). Conversely, no engraftment was observed in mice transplanted with 5000 34HCACE + cells (Supplemental Table S4 ) and very few human cells (0.2%) were detected in one out of 6 mice engrafted with 10,000 34HCACE + cells. Low reconstitution (0.3%) could be observed in one mouse out of 6 when 100,000 34HCACE -cells were injected. One out of 2 mice injected with 50,000 CD34 + CD45 + control cells exhibited a significant level of BM engraftment (70.5%) but when less than 50,000 CD45 + CD34 + cells were injected (4 mice tested), no engraftment was detected (Supplemental Table S4 ).
We then analyzed the phenotype of human repopulating cells with a panel of human-specific antibodies including CD34, CD38, CD45, myeloid (CD33, CD15, CD14), B-lymphoid (CD19) and T- Figure S3) . A rare population (0.11%) of cells co-expressing VEC and CD45 could be detected in more differentiated CD45 high cells (Supplemental Figure S3) . These latter cells were mostly CD34 -and co-expressed myeloid lineage markers (data not shown).
FACS profiles obtained from BM mononuclear cells were identical to that obtained from CB ones except that we could detect more VEC + CD45 -ECs (Supplemental Figure S3 ).
Identification of a VEC low CD45 low DP population in human embryonic YS, AGM and placenta
We investigated whether earlier hematopoietic sites of the developing human conceptus also harbored cells co-expressing VEC and CD45. We thus performed flow cytometry analyzes on human YS, AGM and placenta (Supplemental Table S6 ). In YS and AGM, although VEC and CD45 expression were largely mutually exclusive, a rare, double positive population (0.047+/-0.023 and 0.045+/-0.028% respectively) was detected ( Figure 8A and Supplemental Table S6 ) as previously described in the EL (Oberlin et al., 2010) and herein. In addition, VEC + CD45 -endothelial and VEC -CD45 + hematopoietic subsets were also identified ( Figure 8A ). Frequency of the DP subset in the YS and AGM changed along ontogeny with the highest proportion observed at the earliest stages analyzed (Supplemental Table S6 ). No DP cells were observed in AGM and YS dissected from embryos older than 6.6 week-old (Supplemental Table S6 ). Additional flow-cytometry analysis of CD34 and ACE in combination with VEC and CD45 demonstrated that DP cell-coexpressing VEC and CD45 in the YS and AGM were mainly positive for CD34 ( Figure 8B ) and ACE (data not shown).
In contrast, 5 to 6.3 week placenta showed only few DP cells (0.015+/-0.0033) even at the earliest stages analyzed ( Figure 8A and Supplemental Table S6 ). No DP cells were observed in placenta dissected from embryos older than 6.6 week-old. As in the AGM and YS, endothelial and hematopoietic subsets were also identified ( Figure 8A ). Flow-cytometry analysis of CD34 in combination with VEC and CD45 demonstrated that DP cell-coexpressing VEC and CD45 in the placenta were also mainly positive for CD34 but to a lesser extend compared to the YS and the AGM ( Figure 8B ). In all stages tested, umbilical cord, heart, lung, head and fetal aorta (considered as nonhematopoietic organs) did not contain (<0,01%) DP cells while endothelial and hematopoietic subsets were identified ( Figure 8C and Supplemental Table S6 ).
Extended long term hematopoietic capacity of the 34DP population in the early human embryo
We tested whether the 34DP (VEC Figure 9B ). To compare the proliferative capacity of 34DP to 34HC cells, the total progeny produced from each cell population was measured after 25 days of culture. As shown on Figure 9C the magnitude of amplification of CD45 + cells for 34DP cells was 5.3, 4.1 and 4.7 fold higher than for 34HCs in the EL, the AGM and the YS respectively. We also measured the CD34 + cell production and demonstrated that the magnitude of amplification of CD34 + cells was of 3.4±0.30, 7.1±0.54 and 9.3±0.83 for 34DP cells in the EL, the AGM and the YS respectively, whereas in culture initiated with 34HCs no CD34 amplification could be observed ( Figure 9D ).
Altogether, long-term culture assays clearly showed that similar to the EL, 34DP cells sorted from YS and AGM were able to maintain undifferentiated CD45 low CD34 + progenitors for a longer period of time than 34HCs, and to yield all blood cell progenies with a delayed but prolonged kinetics of hematopoietic differentiation compared to 34HCs.
DISCUSSION
Identification of the different hematopoietic populations operating in the early human embryo and their hierarchical organization is of paramount importance to decipher the cellular and molecular mechanisms associated with self-renewal and differentiation and to design innovative cell based therapies.
In order to distinguish more accurately the earliest HSPCs emerging in the human embryo, we performed here a complete ensemble of phenotypic and functional characterizations of the 34DP and the 34HC EL cells using markers commonly used to identify human HSPC and endothelial cells and identified ACE as a key marker that, associated with VEC, allows discriminating hematopoietic populations endowed with a strong hematopoietic potential from those with less potential.
Identification of 34DPACE + cells at the top of the hierarchy in the human EL
Our extensive phenotypic analysis extended the phenotype of the DP cells (Oberlin et al., 2010a) ACE, a regulator of blood pressure, is a cell surface marker of adult HSPCs (Jokubaitis et al 2008) . It is expressed in all developing blood-forming tissues of the human embryo and fetus (Sinka et al 2012) and has been reported as expressed by the intra-aortic hematopoietic clusters of the AGM, as well as by surrounding ECs (Sinka et al., 2012) . In keeping with this, we demonstrated that ACE is tightly associated with EC and DP cells but not with more mature HCs in the EL. Our results are also in agreement with the fact that human fetal liver derived CD34 + ACE + cells, but not CD34 + ACE -cells, are endowed with LTC-IC potential and sustain multilineage hematopoietic cell engraftment when transplanted into NOD/SCID mice (Sinka et al 2012) . However when splitting EL HSPC into 34DPACE + , 34HCACE + and 34HCACE -cell population we observe a radical change from a more powerful VEC + subpopulation to less powerful VEC -subsets. For that reason we place the 34DPACE + at the top of the EL hematopoietic hierarchy. Since VEC and ACE are progressively lost with time as liver development proceeds, 34DPACE + could thus represent a transient HSPC population harboring endothelial traits and originating from earlier hematopoietic sites. This population will, supposedly, progressively give rise first to 34HCACE+ and then to 34HCACE -cells following the subsequent loss of VEC and ACE (See recapitulative scheme in Figure 10 ).
Cell cycle analysis also demonstrated that cells switched abruptly from an actively dividing to a quiescent state when 34DPACE + , 34HCACE + and 34HCACE -cell populations are considered respectively. Unlike adult bone marrow HSPCs which are mostly quiescent, fetal liver HSPCs are thought to be highly proliferative (Bowie et al., 2007 (Bowie et al., , 2006 Morrison et al., 1995) , leading to a ∼38-fold expansion from E12 to E16 in the mouse (Ema and Nakauchi, 2000) . Here we show that, unexpectedly, the proliferative potential is unequally distributed among the different EL hematopoietic populations. A contrasted proliferation potential has already been demonstrated in the murine AGM, using Fucci reporter mice to visualize the cell-cycle status. A slowing down of cell cycle is observed as cells start to acquire a definitive HSC state immediately before reaching the fetal liver, similar as we report for EL HSCs (Batsivari et al., 2017) . Whether or not this multiplication landscape is conserved when cells reached the fetal liver is yet to be defined. Comparison of the EL hematopoietic cell populations to that of quiescent adult bone marrow HSPC (Arai and Suda, 2007; Wilson et al., 2008) will provide mechanistic insights into how to tailor HSPC expansion ex vivo.
Our phenotypic study combine to in vitro and in vivo hematopoietic analysis not only shed a new light on the hierarchical organization of the human EL HSPC compartment but also confirms that during EHT the hematopoietic lineage seems to be gradual rather than abrupt. Such a hierarchical hematopoietic organization has been described within intra-aortic hematopoietic clusters in the murine and human AGM (Boisset et al., 2014; Rybtsov et al., 2014 and Ivanovs et al., 2014) and in the murine fetal liver (Kieusseian et al., 2012) . Hierarchical organization of the human EL remain largely unexplored at the exception of a recent study which describes a novel surface marker, glycosylphosphatidylinositol-anchored protein GPI-80, that is functionally required for HSPC selfrenewal at fetal stages (Prashad et al., 2014 ). Although we have not addressed the biological value of GPI-80, it will be interesting to investigate whether differences in levels of GPI-80 expression in DP cells can still help to even refine EL HSCP hierarchy at embryonic stages.
Identification of 34DP cells in the early human embryo but not in neonatal or adult hematopoietic tissues
Based on our previous studies in the EL (Oberlin et al., 2010a, b) , we also addressed the question of the biological value of VEC and CD45 expression in the human YS and the AGM to isolate cells carrying a strong amplification and self-renewal potential. We do find DP cells, most of which are positive for CD34 and ACE in these sites. Moreover, the extended long-term hematopoietic capacity in the AGM and the YS is restricted to DP cells. These results are in agreement with studies in the mouse (Taoudi et al., 2005 , Fraser et al., 2003 , North et al., 2002 Nishikawa et al., 1998a) and the human embryo (Ivanovs et al., 2014) showing that the first YS and AGM HSPCs harbored a dual hemato-endothelial phenotype. Furthermore, detection of DP cells as early as 5 weeks of gestation in the human EL and at the same time in the AGM region and YS, two sites of hematopoietic emergence, suggests that the EL is seeded by AGM or YS-derived DP cells.
In contrast to the YS and AGM, the 5 to 9.6 week placentas show only few DP cells. Despite the fact that CD34 + cells are detected as early as week 5 of gestation in the human placenta (Barcena et al., 2009) , repopulating HSPCs are present at week 6 of gestation (Robin et al., 2009 ) although two studies report the presence of transplantable HSPCs only after week 9 of gestation or even later, as determined by xenotransplantation into immunocompromised mice Muench et al., 2017) . These latest observations and the fact that we could only identify few DP cells in the 5-9.6 week placenta highlight the possibility that, contrary to the mouse embryo (Rhodes et al., 2008) , the human embryo placenta may not be a potent site of HSPC emergence. Regarding amplification, our observations are also different from those reported for the mouse placenta that is considered as a site of unbiased HSPC amplification (Gekas et al., 2005; Ottersbach and Dzierzak, 2005) .
As expected, in all stages tested, non-hematopoietic organs as umbilical cord, heart, head and lung, only contain extremely few cells co-expressing VE-cadherin and CD45 (<0.1%). As for the placenta, these DP cells could represent embryonic HSPCs migrating from the YS and the AGM to the EL.
Finally, VEC expression is absent from neonatal and adult hematopoietic tissues. This indicates that the DP fraction progressively loose VEC expression as development proceeds to completely disappear from neonatal stages.
Role of VEC in human HSC emergence, migration and amplification
Self-renewal and multilineage reconstitution is tightly associated with VEC in the early human embryo. Does VEC represent a signature of endothelial origin that disappears with time or is VEC expression associated with hematopoietic-specific molecular pathways to sustain EL hematopoiesis?
VEC is one of the classic Ca 2+ dependent, homophilic adhesion molecules primarily expressed in endothelial cell adherens junctions (Lampugnani et al., 1992) . The intracellular domain of VEC physically interacts with p120 catenin, beta-catenin, alpha-catenin, and the actin cytoskeleton.
Tyrosine phosphorylation of the C-terminus of beta-catenin at Tyr142, or the VE-cadherin intracellular domain at Tyr 658/731 by Src family kinases, alters the binding affinity of beta-catenin to VEC (Lagendijk et al., 2015; Poter et al., 2005; Nelson 2004 ). In addition, VEC was shown to be a critical regulator of TGFß (Rudini et al., 2008) that is also a key regulator of HSPC (Larsson et al., 2003; Yamazaki et al., 2009) . Several reports indicate that the canonical Wnt/beta-catenin signaling pathway plays a pivotal role in hematopoietic stem-and progenitor-cell development (Reya et al., 2005; Ruiz Herguido et al., 2012) . Interplay between beta-catenin and VE-cadherin may modulate the stem-cell properties of newborn HSPCs. Whether this interaction influences HSPC emergence and embryonic migration and how this interaction contributes to sustained HSPC self-renewal warrant further investigation. Such information may bring us closer to dissecting out the self-renewal mechanisms operating in HSPCs ex vivo to further apply these discoveries into clinical applications. 
